All organisms, from bacteria to humans, need to recognize where they are, and respond accordingly. A pathogen must sense its location in the infectious cycle, then produce factors necessary for that site while repressing synthesis of inappropriate factors. Thus, disruption of key regulatory pathways can inhibit a pathogen's ability to infect, indicating useful targets for developing novel antibiotics. In our studies of th Lyme disease bacterium, Borrelia burgdorferi, we discovered that regulation of a new DNA/RNA-binding protein named BpuR is required for mammalian infection. B. burgdorferi regulates production of BpuR, synthesizing it at low levels during mammalian infection processes, and at high levels during colonization of vector ticks. We genetically engineered B. burgdorferi to constitutively produce high levels of BpuR during murine infection, and found the mutant to be significantly impaired in its ability to colonize mice. Transcriptomic analyses (RNA-Seq) demonstrated that BpuR significantly affects expression of approximately 5% of B. burgdorferi operons, disturbing cellular levels of several known virulence factors and metabolic enzymes. We hypothesize that disruption of the processes controlling production of BpuR will significantly inhibit B. burgdorferi infection. The planned studies are designed to elucidate the mechanism by which B. burgdorferi controls expression of this critical regulatory factor, and determine how disrupting that mechanism impacts upon infection processes.

Public Health Relevance

The BpuR protein of the Lyme disease bacterium binds specific sequences of DNA and RNA, and controls expression of numerous virulence factors and essential metabolic enzymes. Bacteria that do not correctly control BpuR levels are severely impaired in ability to cause mammalian infection. Studies in this proposal will determine the mechanisms by which Lyme bacteria control BpuR production, and define how disruption of those mechanisms impacts upon infection processes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI120602-02
Application #
9220718
Study Section
Special Emphasis Panel (ZRG1-IDM-B (80)S)
Program Officer
Ilias, Maliha R
Project Start
2016-02-10
Project End
2018-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
2
Fiscal Year
2017
Total Cost
$185,266
Indirect Cost
$60,266
Name
University of Kentucky
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506